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We describe the development of cell-penetrating inhibitors of Ras and study their ability to inhibit T
cell activation. The inhibitors transduced T cells in a time and concentration-dependent manner and
interacted with endogenous Ras. Anti-CD3/CD28-activated cells when treated with the inhibitors,
exhibited a notable reduction in cell size, diminished proliferative capacity, and were more prone
to apoptosis. Similarly, lymphocytes activated by antigen in vivo, exhibited accelerated apoptosis
when treated with the inhibitors ex vivo. Our data reveal a pro-survival role for Ras in activated pri-
mary T cells and describe a new methodology for regulating its activity.
Structured summary:
MINT-6802882: RAF1 (uniprotkb:P04049) physically interacts (MI:0218) with RAS (uniprotkb:P01112) by
anti tag co-immunoprecipitation (MI:0007)
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Ras proteins are small GTPases that control cell growth, differ-
entiation, and apoptosis [1,2]. The family comprises three mem-
bers, H-Ras, K-Ras and N-Ras with similar function. They regulate
intracellular signalling such as the Raf-1/ERK [3] and PI3 kinase
[4,5] cascades which are essential for survival and proliferation.
Many studies have demonstrated a role for Ras in immune cells.
In T lymphocytes stimulation of the T cell antigen receptor (TCR)
causes rapid accumulation of the active GTP-bound form of Ras
[6], which in combination with other signals leads to cytokine gene
expression and clonal expansion [7–9]. Recent reports have linked
impaired Ras activation to induction of T cell anergy [10,11] high-
lighting the crucial role of this GTPase in determining the ﬁnal out-
come following TCR stimulation. However, the role of Ras during
the different stages of activation of primary human T cells, or its
role in animal models of inﬂammatory disease, has not been fully
delineated.al Societies. Published by Elsevier
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y, Imperial College, 1 AspenleaIn the present study, we describe the generation and testing of
novel protein inhibitors of Ras, which contain the Ras-binding do-
main of Raf-1 (RBD), linked to the TAT protein transduction domain
(PTD). RBD speciﬁcally binds to Ras, while TAT PTD enables heter-
ogeneous proteins and other biological agents to enter cells
[12,13]. We also test the effect of the Ras neutralizing mAb, Y13-
259 [14], when linked to TAT PTD. Our data show that these re-
agents readily enter cells and have a dual function; they diminish
growth and increase apoptosis of lymphocytes stimulated in vitro,
although with varying efﬁciency, suggesting a pro-survival role for
Ras in activated T cells. Furthermore, using a model of T cell med-
iated inﬂammation, we show that lymphocytes activated physio-
logically in vivo are similarly susceptible to apoptosis when
exposed to the TAT-coupled Ras inhibitors.2. Materials and methods
2.1. Cells, Abs, and reagents
Human PBMCs were isolated from heparinized venous blood by
centrifugation over Ficoll-Hypaque (ICN Biomedicals, Aurora, OH)
and cultured in RPMI 1640 medium containing 5% FCS, 2 mM
L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin.
Splenocytes from C57Blk/6 mice were obtained by pushing spleensB.V. Open access under CC BY-NC-ND license.
62 N.M. Malik et al. / FEBS Letters 583 (2009) 61–69through a 70 lm cell strainer (BD Biosciences, Bedford, MA) and
mononuclear cells were puriﬁed by Ficoll-Hypaque. The human
leukemic T cell line Jurkat was maintained in the same medium
as PBMCs and COS-7 cells were cultured in DMEM/10% FCS. All
phosphor-speciﬁc antibodies were from Cell Signaling Technology
(Beverly, MA), to Ras (Y13-259) from Santa Cruz Biotechnology
(Santa Cruz, CA), and to anti-HA tag (mAb 12CA5) from Babco
(Lakeside, CA). For stimulation of human and mouse T cells, the fol-
lowing combination of mAbs were used; anti-human CD3 (clone
HIT3a)/CD28 (clone CD28.2), and anti-mouse CD3 (clone 145-
2C11)/CD28 (clone 37.51) from eBioscience (San Diego, CA). Dyna-
beads coated with sheep anti-rat IgG and sheep anti-mouse IgG
were from Dynal (Oslo, Norway). PD098059 and LY294002 were
obtained from Calbiochem (La Jolla, CA) and farnesylthiosalicylic
acid (FTS) from Biomol (Exeter, UK).
2.2. Expression constructs and puriﬁcation of TAT-fusion proteins
The RBD domain of human Raf-1 gene (amino acids 50–130)
was ampliﬁed with PCR using the forward primer 50-GGAGGT-
ACCCCTTCTAAGACAAGCAACA-30 and the reverse primer 50-GAG-
CATGCTCACAGGAAATCTACTTGAAGT-30. For RBD-CRD (RCRD)
(amino acids 50–220 of Raf-1 which contains the cysteine-rich do-
main adjacent to RBD) the same forward primer was used with the
reverse primer 50-GAGCATGCTCAAGACTCTCGCATACGACG-30. PCR
products were digested with KpnI/SphI and subcloned in frame
into the corresponding sites of the pRSET-TAT-HA vector. This vec-
tor, a kind gift from S. Dowdy (UCSD, CA), has been described pre-
viously and contains an 6xHis epitope for protein puriﬁcation, the
TAT PTD, and the HA tag [15]. TAT-RHA, which contains the HA2
fusogenic peptide from inﬂuenza haemmaglutinin (it is different
from the HA tag) upstream of the RBD domain, was constructed
by commercially synthesizing the HA2-6xHis-TAT segment (Gen-
Script, Piscataway, NJ). The HA2-6xHis-TAT was digested with
XbaI/KpnI and inserted into the corresponding sites of pRSET-
TAT-RBD to generate pRSET-TAT-RHA. DNA sequencing veriﬁed
the accuracy of all expression constructs.A
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Fig. 1. Characterization of puriﬁed TAT-proteins. (A) Schematic representation of the TA
stain. (C) Puriﬁed proteins (a-0.25 lg, b-0.5 lg) probed with the anti-HA mAb, 12CA5. TPuriﬁcation of TAT-fusion proteins was performed under dena-
turing conditions using 8 M urea as previously described [15,16].
The eluted proteins were adjusted to 10% glycerol, and stored at
70 C. To prevent aggregation proteins were kept at concentra-
tions of 0.5 mg/ml. Y13-259 rat IgG1 was puriﬁed from culture
supernatant using protein G-Sepharose (Amersham Biosciences,
Uppsala, Sweden). Synthetic TAT peptide was commercially syn-
thesized (Advanced Biotechnology Centre, Imperial College Lon-
don) and covalently attached to the mAb by sulpho-SMCC cross-
linking (Pierce, Rockford, IL) according to manufacturers
instructions.
2.3. Cell stimulation, immunoprecipitation and Western blotting
For T cell stimulation, human PBMCs were incubated on ice for
10 min with 1 lg/ml each of anti-CD3 and anti-CD28 mAbs, fol-
lowed by 5 min incubation at 37 C after the addition of 1 lg/ml
of anti-mouse cross-linking antibody. Stimulation of splenocytes
was performed as above with mAbs speciﬁc for murine CD3 and
CD28 receptors. Cell lysis, gel electrophoresis and Western blotting
are described in the Supplementary text. For immunoprecipitation
experiments, cells were incubated with TAT-reagents for 90 min,
washed and stimulated with anti-CD3/CD28 mAbs as above. Alter-
natively, COS-7 cells, transfected with a G12V-Ras expressing plas-
mid were cultured for 24 h before incubation with TAT-proteins.
Pre-cleared lysates were incubated with either anti-rat IgG, or
anti-HA mAb and anti-mouse coated Dynabeads. Immune com-
plexes were immunoblotted with Y13-259-HRP to visualize co-
immunoprecipitated Ras.
2.4. Flow cytometry and apoptosis assay
TAT-reagents were labeled with FITC (NHS-Fluorescein, Pierce,
Rockford, IL) and dialyzed extensively against PBS. Cells were incu-
bated with FITC-TAT-reagents as indicated in ﬁgure legends,
washed and treated with trypsin for 5 min at 37 C to eliminate
membrane bound proteins. After washing, cells were ﬁxed and15
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N.M. Malik et al. / FEBS Letters 583 (2009) 61–69 63analyzed on a FACS Calibur. Apoptosis of T lymphocytes stimulated
with anti-CD3/CD28 coated T cell expander Dynabeads (Dynal Bio-
tech, Oslo, Norway) for 24 and 84 h, was measured by ﬂow cytom-
etry after staining with FITC-conjugated Annexin V and propidium
iodide (BD Biosciences, Oxford, UK). Ex vivo apoptosis of murine
lymphocytes isolated from inguinal lymph nodes of mice at 48 h
post-challenge of a delayed type hypersensitivity (DTH) reaction,
was measured after incubation with TAT-GFP control (20 lg/ml)
or TAT-RBD (20 lg/ml) for 4 h. Cell size was assessed by the anal-
ysis of SSC versus FSC ﬂow cytometry plots gated on the live cell
population.
2.5. Carboxyﬂuorescein diacetate succinimidyl ester (CFSE)
proliferation assay
Suspensions of PBMCs (1  106 cells/ml) in warm PBS/0.1% BSA
were labeled with 2 lM CFSE (Molecular Probes, Eugene, OR) for
10 min at 37 C. Staining was quenched with ﬁve volumes of ice-0 minA
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Fig. 2. Cell transduction by puriﬁed TAT-linked proteins. (A) Kinetics of cell transduction
Y13. At the indicated times, cells were collected and treated brieﬂy with or without tryps
20 lg/ml of FITC-conjugated TAT-fusion proteins for 90 min. FITC-TAT-Y13 used at 70 a
FITC-conjugated BSA was used as control for non-speciﬁc binding.cold media and incubated on ice for 5 min. After washings
CFSE-labeled cells were stimulated with anti-CD3/CD28 coated
Dynabeads for 84 h and analyzed by ﬂow cytometry, gating on
the live cells.2.6. Statistics
Statistical analysis was performed using ANOVA, followed by
Dunnet post-hoc test. Data are expressed as mean ± S.E. of the
mean.
3. Results
3.1. Generation of cell-transducing Ras inhibitors
To develop a strategy for inhibition of Ras function in primary
cells, we generated protein cell-transducing inhibitors speciﬁc forFITC-TAT-Y13 
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was established by culturing Jurkat T cells with 20 lg/ml of FITC-conjugated TAT-
in to eliminate non-speciﬁc cell surface binding. (B) Jurkat cells were incubated with
nd 200 nM conﬁrmed the dose dependent manner of cell transduction. 20 lg/ml of
64 N.M. Malik et al. / FEBS Letters 583 (2009) 61–69Ras. These were the neutralizing Y13-259 mAb [14] chemically
crosslinked to the TAT peptide (TAT-Y13), and TAT-fusion proteins
containing the RBD of Raf-1 expressed and puriﬁed from bacteria
(Fig. 1A). TAT-GFP, TAT-RBD and TAT-RCRD also contained the
HA tag; the HA epitope was not included in the TAT-RHA protein
(Fig. 1B and C). Instead TAT-RHA contained at the N-terminus the
fusogenic HA2 peptide from haemagglutinin inﬂuenza. The ability
of FITC labeled TAT-Y13 or TAT-rat IgG control, and TAT-fusion
proteins to transduce Jurkat T cells was conﬁrmed by ﬂow cytom-
etry (Fig. 2A and B). Transduction by TAT-Y13 was observed within
25 min after protein addition to the culture medium reaching max-
imal transduction after 90 min (Fig. 2A). Treatment of cells with
trypsin prior to analysis to eliminate surface bound protein (or
heparin to dislodge proteins bound via charge; not shown), dem-
onstrated that TAT-Y13 was internalized (Fig. 2A). The transduc-
tion ability of TAT-Y13 (Fig. 2B) and of TAT-fusion proteins (not
shown) was concentration dependent. FITC-conjugated BSA was
used as control for non-speciﬁc ﬂuorescence.TAT-
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shown from three similar observations. IgH and IgL denote the heavy and light chain o
experiments of the intensity of the bands that correspond to co-immunoprecipitated Ras
the G12V-Ras mutant were incubated with 20 lg/ml of the indicated TAT-fusion pro
immunoprecipitated Ras was detected by Western blotting. Splenocytes cultured with
stimulated with anti-CD3/CD28 coated beads for 5 min (F). Equivalent amount of lysates
activated forms of c-Raf-1, Akt, and ERK1/2. Protein loading was assessed with an anti-
protein loading according to the intensity of the bands in the t-ERK blot. Results are expr
of 1. (H) Jurkat cells were incubated with 20 lg/ml of TAT-fusion proteins and then s
determined as above. p-ERK, phosphorylated ERK; t-ERK, total ERK; PD98, MEK inhibito
blots in (F) and (G).3.2. Cell-penetrating proteins interact with endogenous Ras
We next investigated whether internalized TAT-Y13 and TAT-
RBD proteins could interact with intracellular Ras. Jurkat cells were
incubated with TAT-Y13 or TAT-rIgG control, lysed and internal-
ized mAb was immunoprecipitated with anti-rat mAb. TAT-Y13
was able to precipitate endogenous Ras as opposed to control anti-
body treated cells (Fig. 3A). Similarly, immunoprecipitation of
internalized TAT-RBD with anti-HA mAb, showed a small but con-
sistent increase in co-immunoprecipitated Ras as compared to the
TAT-GFP control (Fig. 3B and C). The weaker co-immunoprecipita-
tion of Ras with TAT-RBD could reﬂect the smaller pool of accessi-
ble RasGTP, as opposed to total Ras available to TAT-Y13. In
additional experiments, to increase the cell pool of GTP-bound
Ras, COS-7 cells were transfected with the G12V-Ras mutant which
is deﬁcient in GTP hydrolysis, before incubation with TAT-RBD.
Fig. 3D again shows that internalized TAT-RBD associated with
more Ras compared to TAT-GFP control.p-Raf-1
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teins and internalized recombinant proteins were precipitated with anti-HA. Co-
20 lg/ml of the indicated TAT-fusion proteins were left unstimulated (E) or were
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ERK2 antibody. (G) Densitometric analysis of the blots shown in (F) normalized for
essed in arbitrary units in which the TAT-GFP treatment control was set at the value
timulated for 5 min with anti-CD3/CD28 antibodies. ERK1/2 phosphorylation was
r PD098059. The blots in panel (E) were exposed considerably longer compared to
N.M. Malik et al. / FEBS Letters 583 (2009) 61–69 653.3. Ras inhibitors reduce the homeostatic phosphorylation of c-Raf-1,
Akt, and ERK in T cells
To see if the cell-transducing inhibitors have an effect on the
activity of Ras effectors, murine splenocytes cultured with TAT-fu-
sion proteins and cell lysates were Western blotted with phospho-
speciﬁc antibodies to Raf-1, Akt and ERK. In non-stimulated cells
the RBD-containing proteins were able to reduce to varying de-
grees phosphorylation of all three signalling molecules (Fig. 3E).
However, in anti-CD3/CD28 stimulated splenocytes the TAT-cou-
pled inhibitors produced variable, albeit not consistent, inhibition
of Raf-1, Akt and ERK1/2 phosphorylation (Fig. 3F). Densitometric
analysis of the intensity of the bands in Fig. 3F, normalized for pro-
tein loading according to the t-ERK blot (4th panel), showed that
TAT-RBD treatment reduced ERK phosphorylation but not p-Raf-1
or p-Akt, while TAT-RCRD reduced Raf-1 phosphorylation, which
however was not translated into a measurable reduction in the
phosphorylation of the downstream molecules Akt and ERK
(Fig. 3G). Similarly, TAT-RHA treatment resulted in small reduction
in p-Raf-1 and p-Akt, but not of p-ERK (Fig. 3G). Therefore,
although some level of inhibition was produced by TAT-RBD-con-
taining proteins in activated T cells, this reduction was not consis-
tent possibly reﬂecting the strong nature of stimulation caused by
the anti-CD3/CD28 beads. Similarly, no inhibition of ERK1/2 phos-
phorylation was seen in Jurkat cells following TCR stimulation
(Fig. 3H), in contrast to the MEK inhibitor PD098059, used as posi-
tive control, which was inhibitory as expected [17]. These results
could suggest that the TAT-RBD proteins are potent enough to re-
duce the homeostatic activity of Ras-controlled pathways in T cells,
but not the strong burst of activation that follows in vitro stimula-
tion of cells with anti-TCR antibodies.A Unstimulated
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experiment was repeated two additional times with similar results.3.4. TAT-coupled proteins inhibit the increase in size and proliferation
of activated T cells
The strong but transient burst of activation after TCR triggering
is followed by a low but sustained level of activation over a period
of hours. This phase is required for T cell growth, as indicated by
the substantial increase in cell size [18], and for proliferation
[19]. To assess potential effects of the inhibitors over the extended
period of stimulation, cell size was determined by ﬂow cytometry
using FSC versus SSC dot plot analysis. Live cells were sub-divided
into three groups indicative of small non-activated (R1), large acti-
vated (R2), and very large activated cells (R3) (Fig. 4A). Treatment
of anti-CD3/CD28-stimulated cells with PD098059 showed a small
but measurable trend towards reduced cell size (Fig. 4B). However
the reduction was much greater in cells treated with the pan-PI3K
inhibitor, LY294002. The combination of the two inhibitors pro-
duced an even greater reduction in size with approximately 50%
of the cells concentrating in the R1 gate (Fig. 4B). This reduction
was equivalent to that produced by farnesylthiosalicylic acid
(FTS), which delocalizes Ras from the plasma membrane [20], sug-
gesting that the ERK and PI3K pathways cooperate to induce T cell
growth. When cells were stimulated in the presence of TAT-fusion
proteins, a reduction in cell size was noted in the RBD-containing
chimeras as compared to GFP control, with an increase in the num-
ber of cells remaining in the R1 gate (Fig. 4B).
To see if the TAT-fusion proteins inhibit cell proliferation, hu-
man PBMCs were labeled with CFSE, stimulated with anti-CD3/
CD28 mAbs, and 84 h later live cells were analyzed by ﬂow cytom-
etry. In the experiment shown in Fig. 5, up to ﬁve cell divisions are
visible in activated cells, while the vast majority of non-activated
cells fall within a single peak (Fig. 5A). FTS treatment reducedActivated
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66 N.M. Malik et al. / FEBS Letters 583 (2009) 61–69the number of cell divisions, particularly peaks that correspond to
4 and 5 cell divisions (Fig. 5B). Similarly, in cultures containing
cell-permeable Ras inhibitors, a reduction in the number of cell
divisions was clearly visible compared to TAT-GFP treated cultures,
with the most notable reduction in the peaks that represent 3, 4
and 5 cell divisions (Fig. 5C). Statistical analysis of the data shows
that incubation with TAT-RBD-containing proteins reduces the
capacity of cells to undergo multiple divisions (Fig. 5D). The same
result was obtained when BrdU incorporation was used as readout
to assess the effect of TAT-RBD on murine splenocyte proliferation
(Supplementary Fig. 1).
3.5. Increased apoptosis of activated T cells treated with cell-
penetrating inhibitors of Ras
Ras may have a role in preventing apoptosis of stimulated T
cells [21]. Therefore, we investigated whether the TAT-RBD pro-
teins and TAT-T13 were able to increase apoptosis in stimulated
T cells. At 24 h post-stimulation, in cells treated with TAT-RBD-
containing proteins there was 5-fold increase in early apoptotic
cells (positive only for annexin V) and 3–4-fold increases in late
apoptotic/necrotic cells (double positive) compared to that in
PBMCs treated with the TAT-GFP control (Fig. 6A). At 84 h there
were still clear differences between RBD and control proteins,
although the overall cell death had also increased (Fig. 6B). In cellstreated with TAT-Y13 there was a small increase in early apoptotic
cells versus control antibody both at 24 and 84 h (Fig. 6A and B),
although overall this inhibitor was the least potent. FTS was most
effective while the MEK inhibitor PD098059 did not increase apop-
tosis (Fig. 6B). Similar results were obtained when murine spleno-
cytes were used instead of human PBMCs (data not shown). In cells
that were left unstimulated, incubation with TAT-RBD for 24 h re-
sulted in somewhat higher apoptosis as compared to TAT-GFP
treatment, however, the overall apoptosis of non-stimulated cells
signiﬁcantly increased even without any treatment (Fig. 6C, top
row). To bypass this problem we measured apoptosis of non-stim-
ulated cells after 4 h treatment. At this time point while the overall
cell apoptosis remained low, the TAT-RBD-treated culture showed
higher apoptosis compared to TAT-GFP control, suggesting that Ras
activity is required for homeostatic T cell survival (Fig. 6C, lower
row).
To see if the cell-penetrating Ras inhibitors accelerate apoptosis
of cells activated in vivo, we used a model of DTH, which is T cell-
mediated, antigen-driven inﬂammation. Following intradermal
injection of methylated BSA (mBSA) in the paw in previously sen-
sitized mice, swelling occurs as early as 4 h and peaks at 48 h be-
fore resolving after 6–7 days (Supplementary Fig. 2 and 3).
Lymphocytes isolated from inguinal draining LNs of mice chal-
lenged with mBSA for 48 h were placed in culture in the presence
of TAT-RBD or TAT-GFP control for 4 h after which they were dou-
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Fig. 6. TAT-RBD proteins increase apoptosis of activated lymphocytes. Human PBMCs were stimulated for 24 (A) or 84 (B) h with anti-CD3/CD28, stained with annexin V-FITC
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in Fig. 6D, cells cultured ex vivo with TAT-RBD were 2-fold more
apoptotic as compared to TAT-GFP-treated cultures corroborating
the results obtained with the in vitro activation of human PBMCs.4. Discussion
Ras inhibitors suitable for in vivo application will be useful in
down-regulating immune responses and inhibiting growth of cer-
68 N.M. Malik et al. / FEBS Letters 583 (2009) 61–69tain types of cancer. Although pharmacologic inhibitors of post-
translational processing of Ras are available, doubts have been
raised as to their speciﬁcity [22]. We utilized protein transduction
to introduce Ras-inhibitory molecules into cells by linking them to
TAT PTD. We previously used this method to down-modulate NF-
jB signalling in vivo [23]. Protein transduction has been used to
introduce TAT-dominant negative Ras into cells and was shown
to ameliorate airway inﬂammation [24]. Also, transduction of
eoshinophils with TAT-dominant negative Ras, down-modulated
IL5-mediated ERK activity and cell survival [25], and decreased cell
adhesion mediated by beta-2 integrin binding to intracellular
adhesion molecule-1 [26]. We chose inhibitors known for their
high speciﬁcity; the neutralizing Y13-259 mAb [14] and the RBD
of Raf-1. The RBD is the minimum region of Raf-1 that binds to ac-
tive Ras with high afﬁnity (Kd of 20 nM), whereas its afﬁnity for
RasGDP is 3 orders of magnitude lower [27]. We also investigated
whether addition of CRD (residues 139–184) [28], or of the fuso-
genic peptide HA2 from inﬂuenza haemagglutinin [29] could in-
crease potency over RBD alone.
The TAT-linked inhibitors transduced Jurkat cells and interacted
with endogenous Ras (Fig. 2). RBD-containing TAT-fusion proteins
were less effective in precipitating Ras compared to TAT-Y13
(Fig. 3). A possible explanation for this difference could be that
while the Y13-259 mAb binds to both RasGTP and RasGDP, RBD-
containing proteins interact with high afﬁnity only with RasGTP.
In agreement with this explanation, TAT-RBD precipitated more
Ras when added to cells expressing the constitutively active
G12V-Ras mutant (Fig. 3D).
In non-stimulated splenocytes, TAT-fusion inhibitors dimin-
ished phosphorylation of the Ras effectors Raf-1, Akt, and ERK
(Fig. 3D), but only marginally inhibited the strong, although tran-
sient, phosphorylation after TCR stimulation. An explanation for
this result might have to do with the strength of the anti-CD3/
CD28 signal as delivered during in vitro activation. The sustained
activation of the PI3K and ERK pathways determines proliferation
and cell cycle progression [17,30]. In our experiments we con-
ﬁrmed the importance of these pathways in the activation of hu-
man T lymphocytes using pharmacological inhibitors (Fig. 4B).
Similarly, the cell-penetrating Ras inhibitors diminished T cell
activation as demonstrated by the reduction in cell size
(Fig. 4B) and the decrease in the number of cell divisions as
monitored by CFSE staining (Fig. 5) and BrdU incorporation (Sup-
plement Fig. 1).
Next we tested whether the cell-penetrating inhibitors affect
survival of activated lymphocytes. TCR stimulation in the presence
of TAT-RBD proteins resulted in increased apoptosis (Fig. 6), as was
ex vivo apoptosis of lymphocytes activated physiologically during
a DTH reaction (Fig. 6C). The Y13-259 mAb has been shown to in-
hibit Ras signalling in Jurkat cells [14] however, in our study TAT-
Y13 was the least effective among the TAT-coupled Ras inhibitors
tested. A possible explanation may have to do with the different
method of delivery employed. While in the published study a sin-
gle chain Fv version of the antibody was expressed endogenously
most likely resulting in high levels of intracellular antibody, in
our study it was chemically coupled to TAT peptide and added
exogenously. At present, we do not know the fate of the internal-
ized mAb or how much of it targets to activated Ras as this may
be a critical step determining its potency. Also, some variability be-
tween the 3 TAT-fusion proteins has been observed. For example,
TAT-RHA was more effective in inhibiting cell growth (Fig. 4B)
while TAT-RBD was more potent in reducing the number of cell
divisions (Fig. 5C). It is possible that the presence of the hydropho-
bic HA2 peptide in TAT-RHA, which may destabilize endosomes,
has an effect on cell growth. Overall, however, during the course
of these experiments, all the RBD-containing fusion proteins were
inhibitory compared to TAT-GFP control.Ras can be either pro-apoptotic or anti-apoptotic depending on
cell type, context and signal strength. For example, over-expres-
sion of active Ras in Jurkat cells leads to the expression of Fas li-
gand (FasL), whereas dominant negative Ras inhibits FasL
expression in response to TCR stimulation [31]. In contrast, other
studies have shown that Ras can protect cells from apoptosis
[32], one mechanism being via activation of NF-jB and the subse-
quent expression of anti-apoptotic proteins [33]. Our results argue
for a pro-survival role for Ras in activated T cells. Blocking the ERK
and PI3K Ras effector pathways with chemical inhibitors shows
that both cascades contribute to activation-induced T cell growth
(Fig. 4). However, lack of complete inhibition may indicate that
either these inhibitors were not entirely stable over the course of
the experiment (84 h), or that additional independent signalling
pathways exist that are capable of sustaining some T cell growth
during activation. A K-Ras/Raf pathway that operates independent
of MEK/ERK to induce growth during colon cancer progression has
been recently reported [34].
The long-term goal of establishing the protein transduction
technology is to regulate Ras signalling in vivo to tackle diseases
such as autoimmunity and cancer. However, the difﬁculties of
translating this technology into a viable therapeutic option in
the clinic should not be underestimated. Potential obstacles could
be that the protein inhibitors elicit an immune response prevent-
ing their repeated administration but also limiting their useful-
ness as down-modulators of immune responses. Another
potential problem could be unwanted side effects since the inhib-
itors would be capable of penetrating a variety of cell types and
tissues. Also, our incomplete understanding regarding the fate
of internalized TAT-coupled proteins may limit its in vivo applica-
tions. Although association with the endogenous protein target
has been observed, part of the internalized TAT-fusion inhibitors
may be sequestered into intracellular compartments and become
inaccessible [35]. Nevertheless, the testing of the TAT-coupled Ras
inhibitors in animal models of disease will help us in addressing
several critical questions about their in vivo usefulness.
In summary, we demonstrate here the feasibility of using a cell-
permeable version of RBD to regulate the activity of Ras signalling
in activated lymphocytes. TAT-RBD regulates T cell function by
down-modulating TCR-mediated cell growth and proliferation,
but also by inducing apoptosis of activated cells.Acknowledgements
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